|Articles|March 8, 2022
- Pharmaceutical Executive-03-01-2022
- Volume 42
- Issue 3
Pharmaceutical Executive, March 2022 Issue (PDF)
Advertisement
Articles in this issue
about 4 years ago
Pressed Into Action: Measuring Pharma’s Reputation Reversalabout 4 years ago
Biopharma in 2021: Big Gains, Volatile Valuesabout 4 years ago
The Resilience of R&D: Pharma Posted Record Output in 2021about 4 years ago
New Age of Psychedelicsabout 4 years ago
Roads Less Traveledabout 4 years ago
Biopharma Stocks, M&A Sputter Amid More Headwindsabout 4 years ago
Pandemic Accelerates CTV Ascent: How Pharma Can Benefitabout 4 years ago
The Human Factor in Data Security Breachesabout 4 years ago
Tapping the Surge in Useful Contingent Labor MarketAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA’s Advisory Panel Votes in Favor of Updating Covid-19 Vaccine Shots to Target XFG Variant
2
CVS Restores Coverage of Lilly’s Zepbound, Adds Oral Obesity Drug Foundayo
3
WHO Prioritizes Three Experimental Treatments for Bundibugyo Ebola Strain
4
FDA's Timeline for DTC Prescription Drug Ad Oversight
5